Alpha Tau to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Alpha Tau to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Please reach out to your J.P. Morgan representative to schedule 1-on-1 meetings with Mr. Sofer and Mr. Levy.The overview presentation will review some of the Company's recent achievements as well as the outlook for upcoming data milestones
概述演示将回顾公司最近的一些成就以及即将到来的数据里程碑的前景
JERUSALEM, Dec. 11, 2024 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the "Company") (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT, today announced that CEO Uzi Sofer and CFO Raphi Levy will present a corporate overview and update at the J.P. Morgan 43rd Annual Healthcare Conference on Thursday, January 16, 2025 at 9:45am PT / 12:45pm ET, in San Francisco, CA, and will host institutional investor meetings at the event.
耶路撒冷，2024年12月11日（环球新闻通讯）——Alpha Tau Medical Ltd.（"Alpha Tau"或"公司"）（纳斯达克：DRTS，DRTSW），创新的α-辐射癌症疗法Alpha DaRt的开发者，今天宣布首席执行官Uzi Sofer和首席财务官Raphi Levy将在2025年1月16日星期四上午9:45（太平洋时间）/ 下午12:45（东部时间）在加利福尼亚州旧金山的J.P.摩根第43届年度医疗保健大会上进行公司概述和更新，并在活动中为机构投资者主持会议。
| Event: | J.P. Morgan 43rd Annual Healthcare Conference |
| Format: | Presentation and 1-on-1 Meetings |
| Date: | January 16, 2025 |
| Time: | 9:45AM PT – 10:25AM PT |
| Location: | Westin St. Francis, San Francisco, CA |
| 事件： | J.P.摩根第43届年度医疗保健大会 |
| 格式： | 演示和一对一会议 |
| 日期： | 2025年1月16日 |
| 时间： | 太平洋时间9:45 - 10:25 |
| 地点: | 旧金山，威斯汀圣弗朗西斯酒店，加利福尼亚州 |
Webcast: Link located on the "Events & Presentations" page in the Investor Relations section on the Company's website at
网络直播：链接位于公司网站投资者关系部分的“活动与演示”页面上
Please reach out to your J.P. Morgan representative to schedule 1-on-1 meetings with Mr. Sofer and Mr. Levy.
请联系您的摩根大通代表，安排与索弗先生和莱维先生的一对一会议。
About Alpha Tau Medical Ltd.
关于Alpha Tau Medical Ltd.
Founded in 2016, Alpha Tau is an Israeli oncology therapeutics company that focuses on research, development, and potential commercialization of the Alpha DaRT for the treatment of solid tumors. The technology was initially developed by Prof. Itzhak Kelson and Prof. Yona Keisari from Tel Aviv University.
阿尔法塔乌成立于2016年，是一家以色列肿瘤治疗公司，致力于阿尔法达特的研究、开发和潜在商业化，以治疗实体肿瘤。这项技术最初由特拉维夫大学的伊茨哈克·凯尔森教授和约纳·凯萨里教授开发。
About Alpha DaRT
关于阿尔法达特
Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy) is designed to enable highly potent and conformal alpha-irradiation of solid tumors by intratumoral delivery of radium-224 impregnated sources. When the radium decays, its short-lived daughters are released from the sources and disperse while emitting high-energy alpha particles with the goal of destroying the tumor. Since the alpha-emitting atoms diffuse only a short distance, Alpha DaRT aims to mainly affect the tumor, and to spare the healthy tissue around it.
Alpha DaRt（扩散α发射体放射治疗）旨在通过肿瘤内递送含钙-224的来源，实现在固体肿瘤上的高效能和适形α辐射。当钙衰变时，其短生命的子体将从来源中释放并扩散，同时发射高能α粒子，目的是摧毁肿瘤。由于α发射原子仅能扩散短距离，Alpha DaRt旨在主要影响肿瘤，并保护周围的健康组织。
Investor Relations Contact:
IR@alphatau.com
投资者关系联系方式：
IR@alphatau.com
